# DUKE Robotics Corp.: financial statements, quarterly

DUKR · Nasdaq · CIK 1638911 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/dukr.md) · [Financials](/companies/dukr/financials.md) · [Filings](/companies/dukr/filings.md) · [Insiders](/companies/dukr/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/dukr/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | not reported | not reported | not reported | not reported | [72.0](/filings/0001213900-25-110845.md) | [36.0 d](/filings/0001213900-26-026927.md) | not reported | [143](/filings/0001213900-26-088727.md) | [216](/filings/0001213900-25-110845.md) | [18.0 d](/filings/0001213900-26-026927.md) | not reported | [149](/filings/0001213900-26-088727.md) |
| Cost of revenue | $k | not reported | not reported | not reported | not reported | [41.0](/filings/0001213900-25-110845.md) | [30.0 d](/filings/0001213900-26-026927.md) | [8.0](/filings/0001213900-26-059275.md) | [55.0](/filings/0001213900-26-088727.md) | [93.0](/filings/0001213900-25-110845.md) | [42.0 d](/filings/0001213900-26-026927.md) | [33.0](/filings/0001213900-26-059275.md) | [91.0](/filings/0001213900-26-088727.md) |
| Gross profit | $k | not reported | not reported | not reported | not reported | [31.0](/filings/0001213900-25-110845.md) | [6.0 d](/filings/0001213900-26-026927.md) | [(8.0)](/filings/0001213900-26-059275.md) | [88.0](/filings/0001213900-26-088727.md) | [123](/filings/0001213900-25-110845.md) | [(24.0) d](/filings/0001213900-26-026927.md) | [(33.0)](/filings/0001213900-26-059275.md) | [58.0](/filings/0001213900-26-088727.md) |
| Research and development | $k | not reported | not reported | [38.0](/filings/0001213900-25-043291.md) | [78.0](/filings/0001213900-25-075284.md) | [20.0](/filings/0001213900-25-110845.md) | [20.0 d](/filings/0001213900-26-026927.md) | [22.0](/filings/0001213900-26-059275.md) | [24.0](/filings/0001213900-26-088727.md) | [34.0](/filings/0001213900-25-110845.md) | [25.0 d](/filings/0001213900-26-026927.md) | [29.0](/filings/0001213900-26-059275.md) | [32.0](/filings/0001213900-26-088727.md) |
| Operating income | $k | [(173)](/filings/0001213900-24-097438.md) | [(221) d](/filings/0001213900-25-025286.md) | [(230)](/filings/0001213900-25-043291.md) | [(293)](/filings/0001213900-25-075284.md) | [(218)](/filings/0001213900-25-110845.md) | [(283) d](/filings/0001213900-26-026927.md) | [(288)](/filings/0001213900-26-059275.md) | [(250)](/filings/0001213900-26-088727.md) | [(213)](/filings/0001213900-25-110845.md) | [(455) d](/filings/0001213900-26-026927.md) | [(513)](/filings/0001213900-26-059275.md) | [(928)](/filings/0001213900-26-088727.md) |
| Interest expense | $k | not reported | not reported | [23.0](/filings/0001213900-25-043291.md) | not reported | not reported | not reported | [30.0](/filings/0001213900-25-043291.md) | not reported | not reported | not reported | not reported | not reported |
| Net income | $k | [(150)](/filings/0001213900-24-097438.md) | [(214) d](/filings/0001213900-25-025286.md) | [(209)](/filings/0001213900-25-110845.md) | [(278)](/filings/0001213900-25-110845.md) | [(211)](/filings/0001213900-25-110845.md) | [(287) d](/filings/0001213900-26-026927.md) | [(279)](/filings/0001213900-26-088727.md) | [(269)](/filings/0001213900-26-088727.md) | [(230)](/filings/0001213900-25-110845.md) | [(463) d](/filings/0001213900-26-026927.md) | [(921)](/filings/0001213900-26-088727.md) | [(726)](/filings/0001213900-26-088727.md) |
| Diluted EPS | $ per share | [0.00](/filings/0001213900-24-097438.md) | not reported | [0.00](/filings/0001213900-25-043291.md) | [(0.01)](/filings/0001213900-25-075284.md) | [0.00](/filings/0001213900-25-110845.md) | not reported | [(0.13)](/filings/0001213900-26-059275.md) | [(0.12)](/filings/0001213900-26-088727.md) | [0.00](/filings/0001213900-25-110845.md) | not reported | [(0.41)](/filings/0001213900-26-059275.md) | [(0.26)](/filings/0001213900-26-088727.md) |
| Basic EPS | $ per share | [0.00](/filings/0001213900-24-097438.md) | not reported | [0.00](/filings/0001213900-25-043291.md) | [(0.01)](/filings/0001213900-25-075284.md) | [0.00](/filings/0001213900-25-110845.md) | not reported | [(0.13)](/filings/0001213900-26-059275.md) | [(0.12)](/filings/0001213900-26-088727.md) | [0.00](/filings/0001213900-25-110845.md) | not reported | [(0.41)](/filings/0001213900-26-059275.md) | [(0.26)](/filings/0001213900-26-088727.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $k | [2,358](/filings/0001213900-23-085199.md) | [2,281](/filings/0001213900-25-025286.md) | [2,112](/filings/0001213900-24-043217.md) | [1,766](/filings/0001213900-24-066102.md) | [1,436](/filings/0001213900-24-097438.md) | [1,256](/filings/0001213900-26-026927.md) | [1,014](/filings/0001213900-25-043291.md) | [581](/filings/0001213900-25-075284.md) | [361](/filings/0001213900-25-110845.md) | [750](/filings/0001213900-26-088727.md) | [475](/filings/0001213900-26-059275.md) | [6,951](/filings/0001213900-26-088727.md) |
| Current assets | $k | [2,643](/filings/0001213900-23-085199.md) | [2,322](/filings/0001213900-25-025286.md) | [2,135](/filings/0001213900-24-043217.md) | [1,828](/filings/0001213900-24-066102.md) | [1,578](/filings/0001213900-24-097438.md) | [1,355](/filings/0001213900-26-026927.md) | [1,074](/filings/0001213900-25-043291.md) | [828](/filings/0001213900-25-075284.md) | [663](/filings/0001213900-25-110845.md) | [907](/filings/0001213900-26-088727.md) | [813](/filings/0001213900-26-059275.md) | [7,249](/filings/0001213900-26-088727.md) |
| Total assets | $k | [2,823](/filings/0001213900-23-085199.md) | [2,479](/filings/0001213900-25-025286.md) | [2,274](/filings/0001213900-24-043217.md) | [1,950](/filings/0001213900-24-066102.md) | [1,755](/filings/0001213900-24-097438.md) | [1,627](/filings/0001213900-26-026927.md) | [1,343](/filings/0001213900-25-043291.md) | [1,137](/filings/0001213900-25-075284.md) | [988](/filings/0001213900-25-110845.md) | [1,249](/filings/0001213900-26-088727.md) | [1,117](/filings/0001213900-26-059275.md) | [7,513](/filings/0001213900-26-088727.md) |
| Current liabilities | $k | [452](/filings/0001213900-23-085199.md) | [311](/filings/0001213900-25-025286.md) | [311](/filings/0001213900-24-043217.md) | [263](/filings/0001213900-24-066102.md) | [289](/filings/0001213900-24-097438.md) | [345](/filings/0001213900-26-026927.md) | [343](/filings/0001213900-25-043291.md) | [344](/filings/0001213900-25-075284.md) | [362](/filings/0001213900-25-110845.md) | [756](/filings/0001213900-26-088727.md) | [1,311](/filings/0001213900-26-059275.md) | [501](/filings/0001213900-26-088727.md) |
| Total liabilities | $k | [817](/filings/0001213900-23-085199.md) | [671](/filings/0001213900-25-025286.md) | [660](/filings/0001213900-24-043217.md) | [602](/filings/0001213900-24-066102.md) | [617](/filings/0001213900-24-097438.md) | [776](/filings/0001213900-26-026927.md) | [761](/filings/0001213900-25-043291.md) | [759](/filings/0001213900-25-075284.md) | [766](/filings/0001213900-25-110845.md) | [1,149](/filings/0001213900-26-088727.md) | [1,690](/filings/0001213900-26-059275.md) | [867](/filings/0001213900-26-088727.md) |
| Shareholders' equity | $k | [2,006](/filings/0001213900-24-097438.md) | [1,808](/filings/0001213900-26-026927.md) | [1,614](/filings/0001213900-25-110845.md) | [1,348](/filings/0001213900-25-110845.md) | [1,138](/filings/0001213900-25-110845.md) | [851](/filings/0001213900-26-088727.md) | [582](/filings/0001213900-26-088727.md) | [378](/filings/0001213900-26-088727.md) | [222](/filings/0001213900-25-110845.md) | [100](/filings/0001213900-26-088727.md) | [(573)](/filings/0001213900-26-088727.md) | [6,646](/filings/0001213900-26-088727.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(59.0) d](/filings/0001213900-24-097438.md) | [(79.0) d](/filings/0001213900-25-025286.md) | [(169)](/filings/0001213900-25-043291.md) | [(345) d](/filings/0001213900-25-075284.md) | [(225) d](/filings/0001213900-25-110845.md) | [(179) d](/filings/0001213900-26-026927.md) | [(218)](/filings/0001213900-26-059275.md) | [(360) d](/filings/0001213900-26-088727.md) | [(163) d](/filings/0001213900-25-110845.md) | [(70.0) d](/filings/0001213900-26-026927.md) | [(517)](/filings/0001213900-26-059275.md) | [(766) d](/filings/0001213900-26-088727.md) |
| Capital expenditure | $k | [2.0 d](/filings/0001213900-24-097438.md) | [0.0 d](/filings/0001213900-25-025286.md) | not reported | not reported | not reported | [1.0 d](/filings/0001213900-26-026927.md) | [25.0](/filings/0001213900-26-059275.md) | [71.0 d](/filings/0001213900-26-088727.md) | [56.0 d](/filings/0001213900-25-110845.md) | [53.0 d](/filings/0001213900-26-026927.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q2 FY2022 (2022-06-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [54.1](/filings/0001213900-23-085199.md) | [54.5](/filings/0001213900-24-043217.md) | [54.6](/filings/0001213900-24-066102.md) | [54.6](/filings/0001213900-24-097438.md) | [54.5](/filings/0001213900-25-043291.md) | [54.7](/filings/0001213900-25-075284.md) | [54.7](/filings/0001213900-25-110845.md) | [2.2](/filings/0001213900-26-059275.md) | [2.2](/filings/0001213900-26-088727.md) | [54.7](/filings/0001213900-25-110845.md) | [2.3](/filings/0001213900-26-059275.md) | [2.8](/filings/0001213900-26-088727.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 3,425,978 at 2026-08-13, from the cover of the [10-Q filed 2026-08-13](/filings/0001213900-26-088727.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.